RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc. (RGRX) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0000707511 · RGRX · OTC · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0000707511 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) has submitted 760 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2003. As a Healthcare sector company with CIK 0000707511, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is RegeneRx Biopharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent RegeneRx Biopharmaceuticals, Inc. 10-K was filed on 2023-04-11 for fiscal year ending 2023. Historical RGRX 10-K annual reports are available from 1994 through 2023.
Investors researching RegeneRx Biopharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
RGRX SEC Filings · 8 questionsRegeneRx Biopharmaceuticals, Inc. (RGRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 760 filings and access original documents at no cost. RegeneRx Biopharmaceuticals, Inc.'s CIK is 0000707511.